SAKAR Stock Overview
Sakar Healthcare Limited research, develops, manufactures, and markets pharmaceutical products in India.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Sakar Healthcare Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹361.20 |
| 52 Week High | ₹479.00 |
| 52 Week Low | ₹210.00 |
| Beta | 0.51 |
| 1 Month Change | 1.88% |
| 3 Month Change | -14.81% |
| 1 Year Change | 63.29% |
| 3 Year Change | 208.19% |
| 5 Year Change | 455.69% |
| Change since IPO | 606.85% |
Recent News & Updates
Recent updates
Is Sakar Healthcare (NSE:SAKAR) A Risky Investment?
Dec 28
Does Sakar Healthcare (NSE:SAKAR) Have A Healthy Balance Sheet?
Aug 05Is Sakar Healthcare (NSE:SAKAR) A Risky Investment?
Mar 29Here's Why Sakar Healthcare (NSE:SAKAR) Has Caught The Eye Of Investors
Jan 31Is Sakar Healthcare (NSE:SAKAR) Using Too Much Debt?
Dec 01Sakar Healthcare (NSE:SAKAR) Has A Somewhat Strained Balance Sheet
Jul 13Sakar Healthcare (NSE:SAKAR) Has A Somewhat Strained Balance Sheet
Mar 26With EPS Growth And More, Sakar Healthcare (NSE:SAKAR) Is Interesting
Jul 01Here's Why I Think Sakar Healthcare (NSE:SAKAR) Might Deserve Your Attention Today
Mar 23Insider Buying: The Sakar Healthcare Limited (NSE:SAKAR) Chairman & MD Just Bought 7.1% More Shares
Mar 02Has Sakar Healthcare Limited's (NSE:SAKAR) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
Feb 08Does Sakar Healthcare (NSE:SAKAR) Have A Healthy Balance Sheet?
Jan 10Here's Why I Think Sakar Healthcare (NSE:SAKAR) Is An Interesting Stock
Dec 14Should You Rely On Sakar Healthcare's (NSE:SAKAR) Earnings Growth?
Nov 22
Shareholder Returns
| SAKAR | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -2.1% | -2.5% | -2.5% |
| 1Y | 63.3% | 55.2% | 44.5% |
Return vs Industry: SAKAR exceeded the Indian Pharmaceuticals industry which returned 55.3% over the past year.
Return vs Market: SAKAR exceeded the Indian Market which returned 45.3% over the past year.
Price Volatility
| SAKAR volatility | |
|---|---|
| SAKAR Average Weekly Movement | 6.6% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.3% |
Stable Share Price: SAKAR has not had significant price volatility in the past 3 months.
Volatility Over Time: SAKAR's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 297 | Sanjay Shah | www.sakarhealthcare.com |
Sakar Healthcare Limited research, develops, manufactures, and markets pharmaceutical products in India. It provides liquid orals, cephalosporin tablets, capsules, dry powder syrups, dry powder injections, liquid injectable (SVP) in ampoules, vials and lyophilized injections, and oral solid dosages. The company’s product portfolio consists of formulations in approximately 22 therapeutic areas, such as antacid, antimalerial, anticoagulant, laxative, anthelmintic, bronchodilator, anaesthetic, antidepressant, sedative, adrenergic, anti-infective, diuretics, oxytocic, analgesic, antiemetic, antipsychotic, antifungal, PPI, anticonvulsant, anti-inflammatory, antihistamine, and multi vitamins.
Sakar Healthcare Limited Fundamentals Summary
| SAKAR fundamental statistics | |
|---|---|
| Market cap | ₹6.88b |
| Earnings (TTM) | ₹124.73m |
| Revenue (TTM) | ₹1.52b |
55.1x
P/E Ratio4.5x
P/S RatioIs SAKAR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SAKAR income statement (TTM) | |
|---|---|
| Revenue | ₹1.52b |
| Cost of Revenue | ₹814.31m |
| Gross Profit | ₹703.46m |
| Other Expenses | ₹578.73m |
| Earnings | ₹124.73m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 6.55 |
| Gross Margin | 46.35% |
| Net Profit Margin | 8.22% |
| Debt/Equity Ratio | 32.5% |
How did SAKAR perform over the long term?
See historical performance and comparison